cchf
viru
cchfv
orthonairoviru
famili
nairovirida
caus
sever
often
fatal
haemorrhag
fever
human
diseas
first
describ
crimea
becam
known
crimean
haemorrhag
fever
viru
first
isol
congo
name
congo
viru
two
name
converg
cchf
cchf
consid
emerg
diseas
across
globe
mani
countri
report
new
infect
recent
cchf
found
europ
mediterranean
china
central
asia
africa
middl
east
india
figur
report
long
period
case
typic
sporad
season
occur
remot
agricultur
region
ixodid
hard
tick
reservoir
vector
cchfv
commonli
found
dri
semiarid
environ
across
africa
europ
middl
east
numer
wild
domest
anim
includ
cattl
goat
sheep
camel
hare
serv
amplifi
host
bitten
infect
tick
anim
infect
difficult
detect
cycl
cchfv
persist
throughout
tick
lifecycl
enabl
reservoir
infect
long
period
without
vertebr
host
transmiss
human
occur
frequent
among
agricultur
worker
follow
bite
infect
tick
among
slaughterhous
veterinari
worker
expos
blood
tissu
infect
livestock
humantohuman
transmiss
infrequ
arisen
contact
infect
patient
contamin
medic
cchfv
infect
typic
four
distinct
prehaemorrhag
haemorrhag
convalesc
incub
period
rang
day
follow
tick
bite
day
follow
contact
infect
blood
prehaemorrhag
phase
characteris
sudden
onset
wide
rang
nonspecif
symptom
mimic
diseas
last
day
cchfv
infect
may
subclin
asymptomat
peopl
exampl
high
level
seropreval
detect
specif
region
turkey
haemorrhag
phase
gener
week
durat
rapid
progress
haemorrhag
sever
ill
patient
may
experi
rapid
deterior
shock
multiorgan
document
outbreak
fatal
rate
hospitalis
patient
rang
high
averag
mortal
occur
second
week
survivor
recoveri
gener
begin
day
onset
ill
howev
full
recoveri
may
take
longterm
effect
cchfv
infect
studi
well
enough
survivor
determin
whether
specif
complic
exist
cchfv
display
high
degre
sequenc
divers
diverg
l
segment
among
isol
genbank
base
analysi
viral
segment
six
seven
viral
lineagesclad
suggest
lengthi
histori
geograph
dispers
viru
africa
europ
middl
east
asia
genom
divers
greater
tick
mammalian
extens
sequenc
divers
cchfv
like
due
genet
reassort
enhanc
circul
adapt
strain
new
geograph
treatment
confirm
case
cchf
gener
support
care
manag
approv
antivir
treatment
although
antivir
drug
ribavirin
wide
use
base
vitro
activ
clinic
evid
postexposur
prophylaxi
use
ribavirin
controversi
recommend
safe
option
healthcar
provid
highriskdirect
exposur
cchfinfect
patient
fluid
develop
new
therapi
slow
part
due
requir
highcontain
laboratori
lack
suitabl
anim
favipiravir
broadspectrum
rna
inhibitor
shown
promis
tetracyclin
cation
amphiphil
drug
ubiquitin
variant
investig
potenti
antivir
howev
none
clinicalstag
develop
current
safe
effect
cchf
vaccin
wide
avail
human
vaccin
develop
base
cchfv
cultiv
suckl
mous
brain
vaccin
individu
develop
anticchfv
antibodi
neutralis
activ
vaccin
licens
bulgaria
use
small
scale
eastern
europ
unlik
gain
intern
regulatori
approv
due
concern
efficaci
allerg
sever
studi
indic
neutralis
antibodi
alon
insuffici
protect
cchfv
unclear
whether
conserv
neutralis
epitop
present
cchfv
newli
develop
mous
model
mimic
human
cchf
diseas
use
studi
vaccin
candid
recent
studi
vaccin
mice
dna
vaccin
encod
ubiquitinlink
version
cchfv
gc
gn
np
demonstr
effici
prevent
immun
lethal
cchfv
use
mous
model
vaccin
cell
culturebas
vaccin
cchfv
strain
provid
partial
protect
highdos
recombin
vaccin
express
cchfv
glycoprotein
gp
segment
use
modifi
vaccinia
viru
ankara
mva
protect
recipi
anim
day
postchalleng
lethal
challeng
model
adapt
repres
infect
via
tick
howev
similar
studi
use
mva
express
cchfv
nucleoprotein
np
segment
gener
immun
respons
fail
protect
anim
lethal
veterinari
vaccin
may
altern
complementari
approach
human
vaccin
livestock
vaccin
cchf
could
play
import
role
prevent
human
infect
control
exposur
anim
slaughter
well
interrupt
vector
cycl
tick
infect
control
cchfv
wildlif
popul
remain
challeng
howev
current
vaccin
avail
use
although
mva
gp
vaccin
current
evalu
cchfv
classifi
countri
serum
sampl
inactiv
eg
virucid
gamma
ray
formaldehyd
heat
manipul
basic
biosafeti
otherwis
cchf
patient
sampl
present
extrem
biohazard
risk
conduct
maximum
biolog
contain
cchfv
detect
saliva
urin
prehaemorrhag
stage
patient
consist
viral
haemorrhag
fever
vhf
cchfv
also
detect
nasal
conjunctiv
rectal
vagin
swab
sever
thorough
studi
cchf
viral
kinet
need
determin
whether
viral
rna
peak
serum
earlystag
infect
later
urin
recoveri
stage
particular
urin
saliva
sampl
may
desir
easi
collect
handl
cchf
diagnosi
cultur
cchfv
urin
indic
potenti
prolong
viraemia
day
well
potenti
transmiss
risk
recov
rtpcrbase
techniqu
typic
target
nucleoprotein
gene
region
segment
conserv
region
cchfv
genom
across
geograph
cchfv
rna
peak
first
week
symptom
onset
detect
viral
load
vari
consider
among
patient
cchf
indic
moder
case
serum
viral
load
initi
copiesml
sever
case
initi
viral
load
typic
copiesml
copiesml
predict
fatal
quantit
realtim
rtpcr
qrtpcr
better
perform
convent
rtpcr
nest
rtpcr
lower
contamin
rate
higher
sensit
specif
better
laboratori
perform
nest
convent
rtpcr
advis
implement
qrtpcr
improv
assay
perform
viral
load
determin
isotherm
naat
test
develop
base
recombinas
polymeras
amplif
enabl
amplif
singl
temperatur
crude
sampl
may
prove
amen
field
diagnost
lowresourc
nextgener
sequenc
ng
enabl
comprehens
genom
analysi
use
cchfv
howev
complex
expens
approach
current
practic
diagnost
screen
mani
inhous
laboratori
test
primer
design
region
circul
strain
tabl
sever
commerci
rtpcr
kit
avail
typic
primer
design
target
broad
consensu
sequenc
within
segment
includ
sever
european
commiss
mark
ce
diagnost
research
useonli
ruo
label
product
standalon
multiplex
test
format
onlin
supplementari
tabl
serolog
assay
sensit
antigen
variat
gener
less
impact
genet
assay
target
cchfv
n
protein
induc
earli
strong
longlast
immun
respons
activ
cchfv
infect
detect
igm
signific
increas
igg
titr
follow
acut
phase
infect
day
symptom
onset
howev
sever
fatal
case
often
mount
detect
antibodi
detect
anticchfv
igg
indic
current
resolv
infect
often
year
infect
use
surveil
epidemiolog
studi
cchfv
captur
elisa
shown
sensit
ifa
neutralis
viru
neutralis
assay
less
use
diagnosi
sinc
cchfv
elicit
rel
low
level
neutralis
antibodi
use
epidemiolog
vaccin
research
cchfv
neutralis
gener
perform
use
plaqu
reduct
neutralis
day
result
rtpcr
mani
cchfv
serolog
test
use
develop
inhous
assay
limit
valid
tabl
sever
commerci
elisa
igg
igm
ifa
kit
avail
although
primarili
market
ruo
onlin
supplementari
tabl
rdt
leverag
antibodyantigen
captur
agent
elisa
later
flow
strip
format
minim
specimen
process
blood
plasma
swab
enabl
faster
time
result
min
howev
lower
detect
sensit
elisa
due
part
reduc
sampl
volum
rdt
ideal
screen
test
suitabl
field
test
low
infrastructur
although
followup
confirmatori
test
often
requir
rdt
use
effect
screen
triag
suspect
highrisk
case
diseas
ebola
howev
literatur
show
evid
cchf
rdt
develop
primari
challeng
detect
sensit
iggigm
serolog
respons
typic
detect
day
postinfect
often
undetect
sever
fatal
infect
cchf
screen
test
need
abl
distinguish
cchf
type
vhf
particularli
region
vhf
virus
may
endem
maintain
region
natur
reservoir
instanc
multiplex
approach
may
better
option
definit
identif
least
rule
rule
virul
analysi
circul
reservoir
sierra
leon
beadbas
immunoassay
use
detect
igg
antibodi
multipl
pathogen
includ
lassa
ebola
marburg
rift
valley
fever
virus
cchfv
panassay
flavivirus
human
serum
sampl
posit
lassa
ebola
marburg
rift
valley
fever
cchf
flavivirus
alphavirus
multiplex
pcr
approach
develop
univers
array
simultan
identif
ebola
marburg
cchf
lassa
fever
rift
valley
fever
dengu
yellow
fever
well
variola
vaccinia
viru
smallpox
detect
virus
differ
isol
crossreact
emerg
final
qrtpcrbase
cardbas
platform
develop
acut
febril
includ
virus
bacteria
protozoa
achiev
overal
sensit
specif
compar
individu
realtim
rtpcr
addit
febril
agent
panel
member
panel
includ
cchf
recent
commerci
avail
use
beadbas
realtim
taqman
assay
limit
detect
copiesml
onlin
supplementari
tabl
surveil
programm
human
anim
tick
endem
border
nonendem
area
use
monitor
spread
infect
anim
usual
asymptomat
activ
surveil
human
case
detect
reveal
cchfv
circul
seroconvers
anim
good
indic
cchfv
preval
domest
anim
turkey
bulgaria
test
cchfvspecif
igg
antibodi
mean
seropreval
bulgaria
turkey
provinc
report
seropreval
almost
rural
urban
set
similar
random
sampl
surveil
programm
employ
howev
routin
reservoirhost
monitor
broadli
implement
surveil
challeng
lack
serodiagnost
test
suitabl
largescal
anim
clear
guidanc
standardis
surveil
cchfv
anim
health
sector
cost
routin
human
surveil
high
preval
endem
countri
iran
iraq
pakistan
turkey
report
human
case
annual
health
surveil
system
although
uniformli
countri
afghanistan
egypt
oman
saudi
arabia
unit
arab
emir
occasion
human
case
report
surround
nonendem
countri
would
benefit
activ
surveil
system
earli
identif
hot
cchf
surveil
harmonis
case
identif
necessari
enhanc
notif
estim
diseas
burden
well
enabl
earli
warn
genet
epidemiolog
shift
human
anim
tick
nation
cchf
prevent
control
programm
strengthen
support
respect
ministri
health
intern
assist
goal
guidelin
develop
group
cchf
establish
formul
recommend
evalu
optim
implement
develop
guidelin
clinic
well
ongo
effort
toward
roadmap
prioritis
research
product
develop
earli
stage
outbreak
diagnost
test
often
evalu
use
strain
relev
region
diagnost
test
develop
could
acceler
valid
extern
qualiti
control
eqa
use
uptod
clinic
specimen
panel
refer
standard
particularli
sinc
prior
eqa
perform
indic
wide
rang
laboratori
test
sensit
major
laboratori
receiv
high
mark
observ
sensit
rang
serolog
assay
molecular
assay
outlier
low
older
test
method
specif
routin
eqa
studi
includ
rang
cchfv
genotyp
concentr
accur
evalu
compar
diagnost
perform
extent
possibl
patient
specimen
could
characteris
maintain
diagnost
test
evalu
qualiti
assur
absenc
clinic
specimen
recombin
approach
may
need
gener
suffici
quantiti
qualiti
control
cchf
diagnost
test
develop
sourc
clinic
specimen
major
roadblock
molecular
serolog
assay
manufactur
process
requir
substanti
amount
refer
materi
often
compani
develop
inhous
calibr
standard
control
suppli
lottolot
variabl
littl
incent
seek
intern
regulatori
approv
even
commerci
supplier
invest
regulatori
approv
often
subject
market
demand
intern
refer
institut
includ
intern
biolog
refer
custodian
laboratori
provid
refer
materi
specimen
panel
valid
eqaprofici
onlin
supplementari
list
specimen
bank
would
benefici
cchfv
diagnost
develop
howev
effort
face
signific
challeng
given
sporad
natur
human
case
typic
occur
remot
agricultur
region
across
countri
sever
hundr
case
confirm
rtpcr
test
requir
high
infrastructur
laboratori
turnaround
time
day
flexibl
approach
need
outbreak
option
serv
anim
human
popul
poc
nearpoc
molecular
diagnost
platform
significantli
lower
infrastructur
requir
implement
decentralis
poc
instrument
compact
selfcontain
autom
sampl
prepar
healthcar
worker
train
oper
clinic
fieldbas
set
given
rang
assay
alreadi
develop
commerci
platform
like
current
cchfv
rtpcr
assay
could
readili
adapt
poc
cartridgebas
format
analysi
identifi
sever
commerci
sourc
cchf
molecular
diagnost
serolog
well
larg
number
inhous
test
despit
sever
gap
identifi
r
blueprint
detail
understand
cchf
viral
antibodi
kinet
need
across
broad
rang
sampl
type
routin
eqa
use
wellcharacteris
uptod
specimen
panel
would
valuabl
clinic
valid
profici
test
surveil
current
limit
lack
harmonis
avail
valid
serolog
test
develop
novel
nextgener
diagnost
technolog
cchf
would
benefit
refin
set
target
product
profil
tpp
detail
clinic
oper
design
specif
includ
rang
minim
optim
perform
characterist
applicationdriven
tpp
design
support
develop
cchf
diagnost
identifi
acceler
care
minimis
transmiss
risk
poc
diagnost
patient
triag
screen
field
test
syndrom
pcr
panel
expedit
differenti
diagnosi
cchf
vhf
pathogen
ng
monitor
circul
strain
viral
mutat
particularli
assess
sensit
probe
design
use
molecular
diagnost
ongo
initi
includ
cchfspecif
tpp
current
develop
part
